Clinical Trial Detail
Contact
Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| NCT ID | NCT02301156 |
| Title | Ublituximab in Combination With Ibrutinib Versus Ibrutinib Alone in Patients With Previously Treated High-Risk Chronic Lymphocytic Leukemia (CLL) |
| Acronym | GENUINE |
| Recruitment | Completed |
| Gender | both |
| Phase | Phase III |
| Variant Requirements | Yes |
| Sponsors | TG Therapeutics, Inc. |
| Indications | |
| Therapies | |
| Age Groups: | adult | senior |
| Covered Countries | USA | ISR |
CKB BOOST